|
1
|
Di Cesare A, Di Meglio P and Nestle FO:
The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J
Invest Dermatol. 129:1339–1350. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ramirez-Carrozzi V, Sambandam A, Luis E,
Lin Z, Jeet S, Lesch J, Hackney J, Kim J, Zhou M, Lai J, et al:
IL-17C regulates the innate immune function of epithelial cells in
an autocrine manner. Nat Immunol. 12:1159–1166. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Clark RA: Skin-resident T cells: The ups
and downs of on site immunity. J Invest Dermatol. 130:362–370.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li Y, Yu C, Zhu WM, Xie Y, Qi X, Li N and
Li JS: Triptolide ameliorates IL-10-deficient mice colitis by
mechanisms involving suppression of IL-6/STAT3 signaling pathway
and down-regulation of IL-17. Mol Immunol. 47:2467–2474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Simanski M, Rademacher F, Schröder L,
Schumacher HM, Gläser R and Harder J: IL-17A and IFN-γ
synergistically induce RNase 7 expression via STAT3 in primary
keratinocytes. PLoS One. 8:e595312013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang L, Li B, Dang E, Jin L, Fan X and
Wang G: Impaired function of regulatory T cells in patients with
psoriasis is mediated by phosphorylation of STAT3. J Dermatol Sci.
81:85–92. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang XO, Panopoulos AD, Nurieva R, Chang
SH, Wang D, Watowich SS and Dong C: STAT3 regulates
cytokine-mediated generation of inflammatory helper T cells. J Biol
Chem. 282:9358–9363. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou L, Ivanov II, Spolski R, Min R,
Shenderov K, Egawa T, Levy DE, Leonard WJ and Littman DR: IL-6
programs T(H)-17 cell differentiation by promoting sequential
engagement of the IL-21 and IL-23 pathways. Nat Immunol. 8:967–974.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu L, Kitani A, Stuelten C, McGrady G,
Fuss I and Strober W: Positive and negative transcriptional
regulation of the Foxp3 gene is mediated by access and binding of
the Smad3 protein to enhancer I. Immunity. 33:313–325. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miyoshi K, Takaishi M, Nakajima K, Ikeda
M, Kanda T, Tarutani M, Iiyama T, Asao N, DiGiovanni J and Sano S:
Stat3 as a therapeutic target for the treatment of psoriasis: A
clinical feasibility study with STA-21, a Stat3 inhibitor. J Invest
Dermatol. 131:108–117. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fu M and Wang G: Keratin 17 as a
therapeutic target for the treatment of psoriasis. J Dermatol Sci.
67:161–165. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jin L and Wang G: Keratin 17: A critical
player in the pathogenesis of psoriasis. Med Res Rev. 34:438–454.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang L, Jin L, Ke Y, Fan X, Zhang T, Zhang
C, Bian H and Wang G: E3 Ligase Trim21 ubiquitylates and stabilizes
Keratin 17 to induce STAT3 activation in psoriasis. J Invest
Dermatol. 138:2568–2577. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
William DJ, Timothy GB and Dirk ME:
Andrews' diseases of the skin clinical dermatology. China Science
Publishing. (Beijing). 195–198. 2015.
|
|
15
|
Lan W, Wan S, Gu W, Wang H and Zhou S:
Mechanisms behind the inhibition of lung adenocarcinoma cell by
shikonin. Cell Biochem Biophys. 70:1459–1467. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gong K, Zhang Z, Chen Y, Shu HB and Li W:
Extracellular signal-regulated kinase, receptor interacting
protein, and reactive oxygen species regulate shikonin-induced
autophagy in human hepatocellular carcinoma. Eur J Pharmacol.
738:142–152. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gaddipati JP, Mani H, Shefal i, Raj K,
Mathad VT, Bhaduri AP and Maheshwari RK: Inhibition of growth and
regulation of IGFs and VEGF in human prostate cancer cell lines by
shikonin analogue 93/637 (SA). Anticancer Res. 20:2547–2552.
2000.PubMed/NCBI
|
|
18
|
Jang SY, Lee JK, Jang EH, Jeong SY and Kim
JH: Shikonin blocks migration and invasion of human breast cancer
cells through inhibition of matrix metalloproteinase-9 activation.
Oncol Rep. 31:2827–2833. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu L, Qin A, Huang H, Zhou P, Zhang C, Liu
N, Li S, Wen G, Zhang C, Dong W, et al: Shikonin extracted from
medicinal Chinese herbs exerts anti-inflammatory effect via
proteasome inhibition. Eur J Pharmacol. 658:242–247. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen X, Yang L, Oppenheim JJ and Howard
MZ: Cellular pharmacology studies of shikonin derivatives.
Phytother Res. 16:199–209. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li W, Zhang C, Ren A, Li T, Jin R, Li G,
Gu X, Shi R and Zhao Y: Shikonin suppresses skin carcinogenesis via
inhibiting cell proliferation. PLoS One. 10:e01264592015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qiu HY, Fu JY, Yang MK, Han HW, Wang PF,
Zhang YH, Lin HY, Tang CY, Qi JL, Yang RW, et al: Identification of
new shikonin derivatives as STAT3 inhibitors. Biochem Pharmacol.
146:74–86. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu Y, Xu X, Gao X, Chen H and Geng L:
Shikonin suppresses IL-17-induced VEGF expression via blockage of
JAK2/STAT3 pathway. Int Immunopharmacol. 19:327–333. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu L, Wu Y, Cao K, Xu YY, Gao XH, Chen HD
and Geng L: Shikonin inhibits IFN-γ-induced K17 over-expression of
HaCaT cells by interfering with STAT3 signaling. Int J Clin Exp
Pathol. 8:9202–9207. 2015.PubMed/NCBI
|
|
25
|
Yu YJ, Xu YY, Lan XO, Liu XY, Zhang XL,
Gao XH and Geng L: Shikonin induces apoptosis and suppresses growth
in keratinocytes via CEBP-δ upregulation. Int Immunopharmacol.
72:511–521. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ikezoe T, Gery S, Yin D, O'Kelly J,
Binderup L, Lemp N, Taguchi H and Koeffler HP:
CCAAT/enhancer-binding protein delta: A molecular target of
1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer
LNCaP cells. Cancer Res. 65:4762–4768. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Alonzi T, Maritano D, Gorgoni B, Rizzuto
G, Libert C and Poli V: Essential role of STAT3 in the control of
the acute-phase response as revealed by inducible gene inactivation
[correction of activation] in the liver. Mol Cell Biol.
21:1621–1632. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang JM, Ko CY, Chen LC, Wang WL and Chang
WC: Functional role of NF-IL6β and its sumoylation and acetylation
modifications in promoter activation of cyclooxygenase 2 gene.
Nucleic Acids Res. 34:217–231. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ko CY, Chang LH, Lee YC, Sterneck E, Cheng
CP, Chen SH, Huang AM, Tseng JT and Wang JM: CCAAT/enhancer binding
protein delta (CEBPD) elevating PTX3 expression inhibits
macrophage-mediated phagocytosis of dying neuron cells. Neurobiol
Aging. 33:422.e11–422.e25. 2012. View Article : Google Scholar
|
|
30
|
Tang D, Sivko GS and DeWille JW: Promoter
methylation reduces C/EBPdelta (CEBPD) gene expression in the
SUM-52PE human breast cancer cell line and in primary breast
tumors. Breast Cancer Res Treat. 95:161–170. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Agrawal S, Hofmann WK, Tidow N, Ehrich M,
van den Boom D, Koschmieder S, Berdel WE, Serve H and Müller-Tidow
C: The C/EBPδ tumor suppressor is silenced by hypermethylation in
acute myeloid leukemia. Blood. 109:3895–3905. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li M, Zhou W, Yuan R, Chen L, Liu T, Huang
D, Hao L, Xie Y and Shao J: ROCK2 promotes HCC proliferation by
CEBPD inhibition through phospho-GSK3β/β-catenin signaling. FEBS
Lett. 589:5892015. View Article : Google Scholar
|
|
33
|
Wang WJ, Li CF, Chu YY, Wang YH, Hour TC,
Yen CJ, Chang WC and Wang JM: Inhibition of the EGFR/STAT3/CEBPD
axis reverses cisplatin cross-resistance with paclitaxel in the
urothelial carcinoma of the urinary bladder. Clin Cancer Res.
23:503–513. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chuang CH, Wang WJ, Li CF, Ko CY, Chou YH,
Chuu CP, Cheng TL and Wang JM: The combination of the prodrugs
perforin-CEBPD and perforin-granzyme B efficiently enhances the
activation of caspase signaling and kills prostate cancer. Cell
Death Dis. 5:e12202014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sønder SU, Paun A, Ha HL, Johnson PF and
Siebenlist U: CIKS/Act1-mediated signaling by IL-17 cytokines in
context: Implications for how a CIKS gene variant may predispose to
psoriasis. J Immunol. 188:5906–5914. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yerlikaya A, Erdoğan E, Okur E, Yerlikaya
Ş and Savran B: A novel combination treatment for breast cancer
cells involving BAPTA-AM and proteasome inhibitor bortezomib. Oncol
Lett. 12:323–330. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Türker Şener L, Albeniz G, Dinç B and
Albeniz I: iCELLigence real-time cell analysis system for examining
the cytotoxicity of drugs to cancer cell lines. Exp Ther Med.
14:1866–1870. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lin YK, Yang SH, Chen CC, Kao HC and Fang
JY: Using imiquimod-induced psoriasis-like skin as a model to
measure the skin penetration of anti-psoriatic drugs. PLoS One.
10:e01378902015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Van Der Fits L, Mourits S, Voerman JS,
Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens
EP and Lubberts E: Imiquimod-induced psoriasis-like skin
inflammation in mice is mediated via the IL-23/IL-17 axis. J.
Immunol. 182:5836–5845. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Morris RJ, Readio N, Boland K, Johnson K,
Lad S, Singh A, Singh A, Holtorf S and Skaar S: Isolation of mouse
epidermal keratinocytes and their in vitro clonogenic culture. J
Vis Exp. 10:e587012019.
|
|
42
|
Hu Y, Shen F, Crellin NK and Ouyang W: The
IL-17 pathway as a major therapeutic target in autoimmune diseases.
Ann N Y Acad Sci. 1217:60–76. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang JM, Tseng JT and Chang WC: Induction
of human NF-IL6β by epidermal growth factor is mediated through the
p38 signaling pathway and cAMP response element-binding protein
activation in A431 cells. Mol Biol Cell. 16:3365–3376. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
O'Rourke J and Yuan R, DeWille J, O'
Rourke JP and Yuan R: CCAAT/enhancer-binding protein-delta
(C/EBP-δ) is induced in growth-arrested mouse mammary epithelial
cells. J Biol Chem. 272:6291–6296. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Albanesi C, De Pità O and Girolomoni G:
Resident skin cells in psoriasis: A special look at the
pathogenetic functions of keratinocytes. Clin Dermatol. 25:581–588.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen Y, Yan H, Song Z, Chen F, Wang H, Niu
J, Shi X, Zhang D, Zhang N, Zhai Z, et al: Downregulation of TNIP1
expression leads to increased proliferation of human keratinocytes
and severer psoriasis-like conditions in an imiquimod-induced mouse
model of dermatitis. PLoS One. 10:e01279572015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pan YC, Li CF, Ko CY, Pan MH, Chen PJ,
Tseng JT, Wu WC, Chang WC, Huang AM, Sterneck E, et al: CEBPD
reverses RB/E2F1-mediated gene repression and participates in
HMDB-induced apoptosis of cancer cells. Clin Cancer Res.
16:5770–5780. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shan ZL, Zhong L, Xiao CL, Gan LG, Xu T,
Song H, Yang R, Li L and Liu BZ: Shikonin suppresses proliferation
and induces apoptosis in human leukemia NB4 cells through
modulation of MAPKs and c Myc. Mol Med Rep. 16:3055–3060. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Huang WR, Zhang Y and Tang X: Shikonin
inhibits the proliferation of human lens epithelial cells by
inducing apoptosis through ROS and caspase-dependent pathway.
Molecules. 19:7785–7797. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Qiu HY, Zhu X, Luo YL, Lin HY, Tang CY, Qi
JL, Pang YJ, Yang RW, Lu GH, Wang XM, et al: Identification of new
shikonin derivatives as antitumor agents targeting STAT3 SH2
domain. Sci Rep. 7:28632017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yang L, Fan X, Cui T, Dang E and Wang G:
Nrf2 promotes keratinocyte proliferation in psoriasis through
up-regulation of Keratin 6, Keratin 16, and Keratin 17. J Invest
Dermatol. 137:2168–2176. 2017. View Article : Google Scholar : PubMed/NCBI
|
